山东博士95亿卖出的新药“造假”?被诺和诺德索赔60亿!

MedTrend医趋势
19 Feb

去年(2024年)底,诺和诺德公司一款有潜力治疗肾病的药物研发遭遇挫折,该公司将此归咎于原制造商的欺诈行为。新加坡法院于2025年2月14日作出裁决,诺和诺德计划向位于新加坡的KBP Biosciences公司及其创始人兼执行董事长黄振华博士索赔8.3亿美元(约60亿元)。法院指出,该诉讼将在纽约进行。此前,诺和诺德向新加坡法院申请,要求在全球范围内冻结KBP公司及其创始人黄振华的资产,法官批准了...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10